XML 34 R11.htm IDEA: XBRL DOCUMENT
v3.22.1

Balance Sheet Components | 3 Months Ended
--- | ---
Mar. 31, 2022
Balance Sheet Related Disclosures [Abstract] |
Balance Sheet Components | Balance Sheet Components Goodwill Goodwill was $704.4 million and $707.9 million as of March 31, 2022 and December 31, 2021, respectively. The change in the carrying amounts of goodwill during the three months ended March 31, 2022 were due to foreign currency translation and measurement period adjustments. The Company has not recorded any impairment related to goodwill. Intangible Assets, Net Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):
| March 31, 2022 |  | December 31, 2021 |  | Weighted Average Amortization Period (Years)
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |
Percepta product technology | $ | 16,000 |  |  | $ | (7,467) |  |  | $ | 8,533 |  |  | $ | 16,000 |  |  | $ | (7,200) |  |  | $ | 8,800 |  |  | 15
Prosigna product technology | 4,120 |  |  | (641) |  |  | 3,479 |  |  | 4,120 |  |  | (572) |  |  | 3,548 |  |  | 15
Prosigna customer relationships | 2,430 |  |  | (1,134) |  |  | 1,296 |  |  | 2,430 |  |  | (1,013) |  |  | 1,417 |  |  | 5
nCounter Dx license | 46,880 |  |  | (7,292) |  |  | 39,588 |  |  | 46,880 |  |  | (6,511) |  |  | 40,369 |  |  | 15
LymphMark product technology | 990 |  |  | (330) |  |  | 660 |  |  | 990 |  |  | (295) |  |  | 695 |  |  | 7
Decipher product technology | 90,000 |  |  | (9,484) |  |  | 80,516 |  |  | 90,000 |  |  | (7,234) |  |  | 82,766 |  |  | 10
Decipher trade names | 4,000 |  |  | (843) |  |  | 3,157 |  |  | 4,000 |  |  | (643) |  |  | 3,357 |  |  | 5
HalioDx developed technology | 44,781 |  |  | (2,961) |  |  | 41,820 |  |  | 45,640 |  |  | (1,877) |  |  | 43,763 |  |  | 10
HalioDx customer relationships | 4,778 |  |  | (556) |  |  | 4,222 |  |  | 4,870 |  |  | (352) |  |  | 4,518 |  |  | 6
HalioDx customer backlog | 6,778 |  |  | (1,121) |  |  | 5,657 |  |  | 6,908 |  |  | (710) |  |  | 6,198 |  |  | 4
Total finite-lived intangibles | 220,757 |  |  | (31,829) |  |  | 188,928 |  |  | 221,838 |  |  | (26,407) |  |  | 195,431 |  |  | 10.9
In-process research and development | 7,300 |  |  | — |  |  | 7,300 |  |  | 7,300 |  |  | — |  |  | 7,300 |  |  |
Total intangible assets | $ | 228,057 |  |  | $ | (31,829) |  |  | $ | 196,228 |  |  | $ | 229,138 |  |  | $ | (26,407) |  |  | $ | 202,731 |  |  |
Amortization of the finite-lived intangible assets is recognized on a straight-line basis. Amortization expense of $5.5 million and $1.8 million was recognized for the three months ended March 31, 2022 and 2021, respectively. The estimated future aggregate amortization expense as of March 31, 2022 is as follows (in thousands of dollars):
Year Ending December 31, | Amounts
2022 remainder of year | $ | 16,431 |
2023 | 21,908 |
2024 | 21,868 |
2025 | 20,725 |
2026 | 18,844 |
Thereafter | 89,152 |
Total | $ | 188,928 |
Supplies and Inventory As of March 31, 2022 and December 31, 2021, supplies and inventory consisted of $9.1 million and $8.2 million, respectively, of lab supplies and reagents consumed in the performance of testing services, and $3.3 million and $3.0 million, respectively, of inventory related to raw materials consumed in contract manufacturing process as well as finished diagnostic kits sourced from third parties related to product sales. Accrued Liabilities Accrued liabilities consisted of the following (in thousands of dollars):
| March 31, 2022 |  | December 31, 2021
Accrued compensation expenses | $ | 29,525 |  |  | $ | 30,792 |
Accrued other | 9,018 |  |  | 8,683 |
Total accrued liabilities | $ | 38,543 |  |  | $ | 39,475 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration